<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ACC</journal-id>
<journal-id journal-id-type="hwp">spacc</journal-id>
<journal-title>European Heart Journal: Acute Cardiovascular Care</journal-title>
<issn pub-type="ppub">2048-8726</issn>
<issn pub-type="epub">2048-8734</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2048872612471215</article-id>
<article-id pub-id-type="publisher-id">10.1177_2048872612471215</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Acute coronary syndromes</subject>
<subj-group subj-group-type="heading">
<subject>Clinical practice</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Joyce</surname><given-names>Emer</given-names></name>
<xref ref-type="aff" rid="aff1-2048872612471215">1</xref>
<xref ref-type="aff" rid="aff2-2048872612471215">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fabre</surname><given-names>Aurelie</given-names></name>
<xref ref-type="aff" rid="aff3-2048872612471215">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mahon</surname><given-names>Niall</given-names></name>
<xref ref-type="aff" rid="aff1-2048872612471215">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-2048872612471215"><label>1</label>Mater Misericordiae University Hospital, Dublin, Ireland</aff>
<aff id="aff2-2048872612471215"><label>2</label>Leiden University Medical Center, Leiden, The Netherlands</aff>
<aff id="aff3-2048872612471215"><label>3</label>St Vincent’s University Hospital, Dublin, Ireland</aff>
<author-notes>
<corresp id="corresp1-2048872612471215">Emer Joyce, Department of Cardiology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland. Email: <email>emerjoyce@yahoo.co.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>2</volume>
<issue>1</issue>
<fpage>77</fpage>
<lpage>83</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>10</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>11</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p>Cardiotoxicity is a rare but serious complication of hydroxychloroquine, a 4-aminoquinoline increasingly used in the treatment of rheumatological disorders. We describe typical clinical, echocardiographic, and histological features of this rare condition according to the currently available literature, illustrated with a recent new biopsy-proven case of hydroxychloroquine cardiotoxicity in a 52-year-old female with rheumatoid arthritis. Presentation in this case was of a rapidly progressive decompensated biventricular cardiomyopathy associated with recurrent biomarker elevations, conduction system disease, and possibly neuromyotoxicity. Death occurred suddenly 2 months after diagnosis despite drug discontinuation and clinical improvement. The potential role of cardiac magnetic resonance delayed gadolinium enhancement imaging in the prognosis of this toxic cardiomyopathy is also introduced. This case-based literature review highlights that, although rare, hydroxychloroquine cardiotoxicity can be fatal, particularly if irreversible histopathological changes have occurred prior to drug discontinuation. Given this, regular screening with 12-lead electrocardiography and transthoracic echocardiography to detect conduction system disease and/or biventricular morphological or functional changes should be considered in hydroxychloroquine-treated patients in addition to recommended ophthalmological screening.</p>
</abstract>
<kwd-group>
<kwd>Cardiomyopathy</kwd>
<kwd>cardiotoxicity</kwd>
<kwd>endomyocardial biopsy</kwd>
<kwd>heart failure</kwd>
<kwd>hydroxychloroquine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2048872612471215" sec-type="intro">
<title>Introduction</title>
<p>Hydroxychloroquine (HCQ) is a 4-aminoquinoline which differs from chloroquine (CQ) in the addition of a hydroxyl group. Initially used as antimalarials, both drugs have now become mainstays in the management of rheumatic diseases principally systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).<sup><xref ref-type="bibr" rid="bibr1-2048872612471215">1</xref>,<xref ref-type="bibr" rid="bibr2-2048872612471215">2</xref></sup> Evidence suggesting HCQ is less toxic than CQ has led to its increased use.<sup><xref ref-type="bibr" rid="bibr3-2048872612471215">3</xref></sup> Retinal toxicity is the most well-recognized complication of long-term use of these agents, but less frequently cardiotoxicity and neuromyotoxicity can also occur. To date, up to 70 cases of cardiotoxicity have been reported in the literature, although less than half of these have been proven on endomyocardial biopsy. In the past, CQ has been predominantly implicated,<sup><xref ref-type="bibr" rid="bibr4-2048872612471215">4</xref><xref ref-type="bibr" rid="bibr5-2048872612471215"/><xref ref-type="bibr" rid="bibr6-2048872612471215"/><xref ref-type="bibr" rid="bibr7-2048872612471215"/><xref ref-type="bibr" rid="bibr8-2048872612471215"/><xref ref-type="bibr" rid="bibr9-2048872612471215"/>–<xref ref-type="bibr" rid="bibr10-2048872612471215">10</xref></sup> but more recently several reports of HCQ-induced cardiomyopathy have emerged,<sup><xref ref-type="bibr" rid="bibr5-2048872612471215">5</xref>,<xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref><xref ref-type="bibr" rid="bibr12-2048872612471215"/><xref ref-type="bibr" rid="bibr13-2048872612471215"/><xref ref-type="bibr" rid="bibr14-2048872612471215"/><xref ref-type="bibr" rid="bibr15-2048872612471215"/><xref ref-type="bibr" rid="bibr16-2048872612471215"/><xref ref-type="bibr" rid="bibr17-2048872612471215"/><xref ref-type="bibr" rid="bibr18-2048872612471215"/><xref ref-type="bibr" rid="bibr19-2048872612471215"/>–<xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup> likely reflecting its increased prevalence of use. Reported cases have occurred predominantly in SLE including discoid lupus rather than RA; more recently, a case has also been reported in scleroderma.<sup><xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref></sup> To our knowledge, only four other cases of biopsy-proven HCQ cardiotoxicity in patients with isolated RA have been reported.<sup><xref ref-type="bibr" rid="bibr5-2048872612471215">5</xref>,<xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref>,<xref ref-type="bibr" rid="bibr19-2048872612471215">19</xref></sup> We present an additional case in a 52-year-old female with a history of connective tissue disease and venous thromboembolism presenting with refractory New York Heart Association (NYHA) functional class 2–3 dyspnoea and intermittent chest pain over a 2-year period in association with recurrent biomarker elevations, conduction system disease on 12-lead electrocardiograph (ECG), and rapidly evolving non-ischaemic pattern biventricular dysfunction.</p>
</sec>
<sec id="section2-2048872612471215" sec-type="cases">
<title>Case report</title>
<p>A 52-year-old woman was admitted to our tertiary referral hospital in September 2010 for further investigation and work up of progressively worsening NYHA class 2–3 dyspnoea over a period of 4–6 weeks, associated with four-pillow orthopnoea, episodic paroxysmal nocturnal dyspnoea, and profound fatigue. She had also noted three episodes of chest pain unrelated to exertion. She had been extensively investigated for similar symptoms leading to three hospital admissions over the previous 2-year period. Background medical history was significant for a number of conditions, including RA (since age 18), venous thromboembolism (deep venous thrombosis and pulmonary embolism complicating a left total knee replacement in January 2009), hypertension, and chronic kidney disease (renal biopsy had not been performed). Medications included warfarin, HCQ (400 mg daily since 1995), maintenance-dose oral steroids (prednisolone 5–10 mg), and bisoprolol 5 mg once daily. She was an ex-smoker. Family history was negative for ischaemic heart disease, cardiomyopathy, or other inherited conditions.</p>
<p>On physical examination, she was haemodynamically stable, in sinus rhythm, and had no overt clinical evidence of heart failure. She had a proximal myopathy predominantly affecting the upper limbs. Troponin I and creatinine kinase – both intermittently elevated over the previous 2-year period – were once again elevated at 0.73 µg/l and 577 U/l respectively. B-type natriuretic peptide was 1560 pg/ml. 12-lead ECG showed a new complete left bundle branch block since her last hospitalization 5 months previously. Echocardiography, performed on a number of occasions over the previous 2-year period, had repeatedly shown preserved biventricular systolic function associated with concentric left ventricular (LV) hypertrophy. Repeat echocardiography now showed global LV systolic dysfunction with an LV ejection fraction of 30–35%, at least mild concentric LV hypertrophy, restrictive stage diastolic dysfunction, and reduced right ventricular (RV) function. No significant valvular regurgitation was present. Repeat left heart catheterization reaffirmed the absence of significant coronary artery disease with TIMI 3 flow in all vessels. Left ventriculogram confirmed at least moderately reduced LV systolic function and elevated LV end-diastolic pressure. Invasive haemodynamic studies revealed significantly reduced cardiac output (2.0 l/min) and elevated pulmonary vascular resistance (4.5 Wood units). Cardiac magnetic resonance (CMR) imaging – performed several months previously – showed normal LV volumes with biventricular hypertrophy (LV mass index 114 g/m<sup>2</sup>) with overall preserved LV function and moderately reduced RV function. Post gadolinium, patchy areas of delayed gadolinium enhancement (DGE) were found in a non-ischaemic distribution in the septum and mid-wall as well as the apical anterior wall.</p>
<p>Respiratory work up ruled out new pulmonary thromboembolic episodes or significant parenchymal lung disease. RV endomyocardial biopsy was subsequently performed. Histology revealed myocyte hypertrophy with focal areas of myocyte damage and marked interstitial fibrosis. In addition, vacuoles were noted in the cytoplasm of some cardiomyocytes, some containing central nuclei. Further processing by electron microscopy showed cytoplasmic granules, some of which contained curvilinear character and occasional myelin like configuration – so called ‘myeloid bodies’ – confirming the diagnosis of HCQ-induced cardiomyopathy. The drug was immediately discontinued and standard guidelines-based heart failure treatment was commenced.</p>
<p>On review 1 month later, she had improved by ≥1 NYHA class without any recurrence of acute heart failure or other symptoms. 12-lead ECG and echocardiography remained unchanged. Further discussion on options such as device therapy and transplant evaluation were deferred pending further optimization of her heart failure treatment. Thirteen days later, the patient died suddenly at home. Post-mortem examination was not carried out.</p>
</sec>
<sec id="section3-2048872612471215" sec-type="discussion">
<title>Discussion</title>
<p>Antimalarial-related cardiotoxicity most commonly manifests clinically as a restrictive or dilated cardiomyopathy or with conduction system abnormalities including atrioventricular block and bundle branch block.<sup><xref ref-type="bibr" rid="bibr4-2048872612471215">4</xref><xref ref-type="bibr" rid="bibr5-2048872612471215"/><xref ref-type="bibr" rid="bibr6-2048872612471215"/>–<xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref>,<xref ref-type="bibr" rid="bibr9-2048872612471215">9</xref><xref ref-type="bibr" rid="bibr10-2048872612471215"/><xref ref-type="bibr" rid="bibr11-2048872612471215"/><xref ref-type="bibr" rid="bibr12-2048872612471215"/><xref ref-type="bibr" rid="bibr13-2048872612471215"/>–<xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref>,<xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref><xref ref-type="bibr" rid="bibr17-2048872612471215"/><xref ref-type="bibr" rid="bibr18-2048872612471215"/><xref ref-type="bibr" rid="bibr19-2048872612471215"/>–<xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup> The most frequent presenting symptoms relate to decompensated left or biventricular failure as illustrated above. However, also as in our case, non-specific chest discomfort may be a presenting or co-existent feature<sup><xref ref-type="bibr" rid="bibr12-2048872612471215">12</xref>,<xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref>,<xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref></sup> as can presyncope associated with conduction disease<sup><xref ref-type="bibr" rid="bibr12-2048872612471215">12</xref>,<xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref></sup> or atrial arrhythmias.<sup><xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref></sup> One patient presented with a generalized tonic-clonic seizure in the setting of sinus arrest.<sup><xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref></sup> In-hospital ventricular arrhythmias in the setting of a prolonged QT interval have been described;<sup><xref ref-type="bibr" rid="bibr18-2048872612471215">18</xref>,<xref ref-type="bibr" rid="bibr21-2048872612471215">21</xref></sup> in both cases, QT interval shortened following discontinuation of the drug.</p>
<p>Clinical features of other toxicities may also be present. A review by Costedoat-Chalumeau et al. in 2007<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref></sup> noted out of 25 patients with CQ- or HCQ-related congestive heart failure, associated toxicity was present in 15 (myopathy in 12, neuropathy in five, and retinopathy in six). In a new case reported by the same authors, concerning severe cardiotoxicity leading to heart transplantation due to use of both HCQ and CQ over a 9-year period, retinal toxicity and neuromyotoxicity were also present.<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref></sup> The most common manifestation of neuromyotoxicity is a bilateral progressive proximal weakness of the lower extremities with variable polyneuropathy.<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref>,<xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref></sup> Proximal myopathy was present in this case, although muscle biopsy to confirm antimalarial toxicity as the cause of this finding had not been performed. Retinopathy, the most well-known complication of these drugs, may manifest as a spectrum of changes from asymptomatic and reversible pigment changes to visual loss persisting or progressing after drug discontinuation.<sup><xref ref-type="bibr" rid="bibr22-2048872612471215">22</xref>,<xref ref-type="bibr" rid="bibr23-2048872612471215">23</xref></sup></p>
<p>Prognosis in antimalarial cardiotoxicity can vary from death to cardiac transplantation to partial or complete improvement in cardiac function.<sup><xref ref-type="bibr" rid="bibr5-2048872612471215">5</xref>,<xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref>,<xref ref-type="bibr" rid="bibr8-2048872612471215">8</xref>,<xref ref-type="bibr" rid="bibr10-2048872612471215">10</xref>,<xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref>,<xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref><xref ref-type="bibr" rid="bibr14-2048872612471215"/><xref ref-type="bibr" rid="bibr15-2048872612471215"/><xref ref-type="bibr" rid="bibr16-2048872612471215"/><xref ref-type="bibr" rid="bibr17-2048872612471215"/><xref ref-type="bibr" rid="bibr18-2048872612471215"/><xref ref-type="bibr" rid="bibr19-2048872612471215"/>–<xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref>,<xref ref-type="bibr" rid="bibr24-2048872612471215">24</xref><xref ref-type="bibr" rid="bibr25-2048872612471215"/>–<xref ref-type="bibr" rid="bibr26-2048872612471215">26</xref></sup> Two case reports have described successful orthotopic heart transplantation.<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref>,<xref ref-type="bibr" rid="bibr10-2048872612471215">10</xref></sup> Indication in both cases was refractory congestive heart failure 3 months after drug discontinuation. In the review by Costedoat-Chalumeau et al.,<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref></sup> of the 25 congestive heart failure cases described, death occurred in 11 (46%) and partial or complete improvement was seen in eight out of 12 cases where the drug was discontinued. Meanwhile regression of conduction disease appears to be rare – out of 15 patients with conduction disorders in which the causative agent was discontinued, only three had resolution of the disturbance.<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref></sup> Considering cases published since this review,<sup><xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref><xref ref-type="bibr" rid="bibr14-2048872612471215"/><xref ref-type="bibr" rid="bibr15-2048872612471215"/><xref ref-type="bibr" rid="bibr16-2048872612471215"/><xref ref-type="bibr" rid="bibr17-2048872612471215"/><xref ref-type="bibr" rid="bibr18-2048872612471215"/><xref ref-type="bibr" rid="bibr19-2048872612471215"/>–<xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup> death occurred in two patients. Both were middle-aged females with a long-standing history of SLE taking 400 mg HCQ daily for &gt;10 years; both died shortly after presentation with acute heart failure despite drug discontinuation.<sup><xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref>,<xref ref-type="bibr" rid="bibr17-2048872612471215">17</xref></sup> Partial or complete improvement in symptoms and/or echocardiographic parameters (ranging from 3 months to 1 year) occurred in the remainder of cases;<sup><xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref><xref ref-type="bibr" rid="bibr14-2048872612471215"/><xref ref-type="bibr" rid="bibr15-2048872612471215"/>–<xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref>,<xref ref-type="bibr" rid="bibr18-2048872612471215">18</xref><xref ref-type="bibr" rid="bibr19-2048872612471215"/>–<xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup> of note, complete histological improvement was also documented in one of these cases.<sup><xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup></p>
<p>Echocardiography plays a key adjunctive role in the diagnosis of HCQ cardiotoxicity. Diffusely thickened ventricular walls on transthoracic echocardiography are one of the hallmarks of this form of cardiomyopathy<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref>,<xref ref-type="bibr" rid="bibr12-2048872612471215">12</xref>,<xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref>,<xref ref-type="bibr" rid="bibr17-2048872612471215">17</xref><xref ref-type="bibr" rid="bibr18-2048872612471215"/><xref ref-type="bibr" rid="bibr19-2048872612471215"/>–<xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup> and were seen from earlier on in our patient’s course. In one report where the patient went on to undergo successful orthotopic heart transplantation, interventricular septal thickness in the explanted heart measured 20 mm.<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref></sup> Biatrial enlargement<sup><xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref>,<xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref>,<xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref><xref ref-type="bibr" rid="bibr17-2048872612471215"/>–<xref ref-type="bibr" rid="bibr18-2048872612471215">18</xref></sup> and restrictive physiology<sup><xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref>,<xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref>,<xref ref-type="bibr" rid="bibr19-2048872612471215">19</xref></sup> are frequently associated (<xref ref-type="fig" rid="fig1-2048872612471215">Figure 1a</xref> and <xref ref-type="fig" rid="fig1-2048872612471215">b</xref>). Such findings, in the absence of significant systolic dysfunction, may be the predominant structural abnormalities seen on echocardiogram<sup><xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref>,<xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref>,<xref ref-type="bibr" rid="bibr18-2048872612471215">18</xref></sup> or may precede the development of systolic dysfunction as in this case.<sup><xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref>,<xref ref-type="bibr" rid="bibr12-2048872612471215">12</xref></sup> In cases with systolic dysfunction, LV ejection fraction is frequently severely reduced.<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref>,<xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref>,<xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref>,<xref ref-type="bibr" rid="bibr17-2048872612471215">17</xref>,<xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup> Although ventricular chamber sizes are frequently normal as in our case, LV and/or RV dilatation have been reported.<sup><xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref>,<xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref>,<xref ref-type="bibr" rid="bibr18-2048872612471215">18</xref>,<xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup> Mitral regurgitation of varying degrees has been reported with one recent case study documenting severe mitral regurgitation likely due to papillary muscle hypertrophy and tethering.<sup><xref ref-type="bibr" rid="bibr12-2048872612471215">12</xref>,<xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref>,<xref ref-type="bibr" rid="bibr16-2048872612471215">16</xref>,<xref ref-type="bibr" rid="bibr18-2048872612471215">18</xref></sup></p>
<fig id="fig1-2048872612471215" position="float">
<label>Figure 1.</label>
<caption>
<p>Findings on imaging modalities in support of the diagnosis of hydroxychloroquine cardiomyopathy. (a) Pulse-wave Doppler of mitral inflow on 2-dimensional transthoracic echocardiography shows increased E-wave peak velocity to A-wave peak velocity ratio (E/A) of &gt;1.5 associated with reduced deceleration time of &lt;160 m/s suggestive of restrictive physiology. (b) Pulse-wave tissue Doppler imaging at the septal mitral annulus shows significantly reduced early diastolic relaxation velocity (0.02 m/s) confirming restrictive pattern diastolic dysfunction. In addition, markedly elevated E/E′(ratio of mitral inflow E-wave peak velocity to tissue Doppler early diastolic velocity) of &gt;15 is shown, suggestive of significantly elevated left ventricular filling pressures. (c and d) Cardiac magnetic resonance 4-chamber (c) and 2-chamber (d) delayed gadolinium enhancement imaging illustrating areas of patchy enhancement throughout the mid-wall, particularly in the septum and apical anterior walls (arrows).</p>
</caption>
<graphic xlink:href="10.1177_2048872612471215-fig1.tif"/>
</fig>
<p>CMR may serve as an increasingly important diagnostic modality in antimalarial cardiotoxicity for a number of reasons. Firstly, it is the reference standard for the assessment of LV and RV function and morphology, the latter also commonly abnormal in antimalarial cardiotoxicity.<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref>,<xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref><xref ref-type="bibr" rid="bibr12-2048872612471215"/>–<xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref>,<xref ref-type="bibr" rid="bibr17-2048872612471215">17</xref>,<xref ref-type="bibr" rid="bibr18-2048872612471215">18</xref></sup> Secondly, CMR also plays a primary role in the exclusion of differential diagnoses. Although rare, myocarditis is one of the recognized cardiovascular sequelae of RA<sup><xref ref-type="bibr" rid="bibr27-2048872612471215">27</xref></sup> and is clearly visualized on CMR as a hyperintense area or areas on T2-weighted MRI sequences, not seen in this case. Restrictive cardiomyopathy in particular cardiac amyloidosis was an important differential diagnosis in our case due to both the past history and echocardiographic findings; however, CMR did not show the typical imaging features suggestive of cardiac amyloid deposition. Another infiltrative cardiomyopathy, cardiac sarcoidosis, was also considered given that it has been associated with conduction system disease on presentation, female predominance, and a higher incidence of abnormal wall thickness, all relevant features to this case.<sup><xref ref-type="bibr" rid="bibr28-2048872612471215">28</xref></sup> However, once again, CMR, shown to be more than twice as sensitive for diagnosing cardiac sarcoidosis than current consensus criteria<sup><xref ref-type="bibr" rid="bibr29-2048872612471215">29</xref></sup> did not show any evidence of the typical ‘punched out’ appearance associated with this cardiomyopathy. Lastly, CMR may also play a role in prognosis through its assessment of the degree of fibrosis as determined by DGE imaging. The presence of DGE in non-ischaemic cardiomyopathies predicts an 8-fold increased risk of an adverse cardiac outcome.<sup><xref ref-type="bibr" rid="bibr30-2048872612471215">30</xref></sup> In the current case, patchy areas of diffuse DGE were present in a non-ischaemic distribution in the septum, mid-wall, and apical anterior wall predating the development of LV systolic dysfunction (<xref ref-type="fig" rid="fig1-2048872612471215">Figure 1c</xref> and <xref ref-type="fig" rid="fig1-2048872612471215">d</xref>); the patient was admitted with decompensated heart failure 4 months later with subsequent biopsy confirming marked interstitial fibrosis. Sudden death, most likely due to a malignant ventricular arrhythmia, occurred less than 2 months later. The possibility of CMR as a potential prognostic indicator and/or monitoring tool in future cases of HCQ and other toxic cardiomyopathies – perhaps suggesting earlier referral for device therapy and/or cardiac transplantation if fibrosis persists despite drug discontinuation – requires further research.</p>
<p>Endomyocardial biopsy was the key diagnostic test in this case. Histology is essential to provide an accurate diagnosis and exclude differential diagnoses, including amyloidosis, myocarditis, and sarcoidosis. The pathological ﬁndings in HCQ cardiotoxicity were first reported by Piette et al.<sup><xref ref-type="bibr" rid="bibr31-2048872612471215">31</xref></sup> and include enlarged and vacuolated cells on light microscopy and the presence of myelinoid and curvilinear bodies – thought to represent abnormal lysosomes – within cardiac myocytes on transmission electron microscopy (<xref ref-type="fig" rid="fig2-2048872612471215">Figure 2</xref>). Curvilinear bodies in particular appear to be the most specific histological indicator of antimalarial-related cardiotoxicity and these structures are not seen in differential diagnoses of some of the other pathological findings, such as other toxic cardiomyopathies or Fabry’s disease.<sup><xref ref-type="bibr" rid="bibr4-2048872612471215">4</xref>,<xref ref-type="bibr" rid="bibr5-2048872612471215">5</xref>,<xref ref-type="bibr" rid="bibr8-2048872612471215">8</xref>,<xref ref-type="bibr" rid="bibr25-2048872612471215">25</xref></sup> Histopathological findings may persist for years after drug discontinuation.<sup><xref ref-type="bibr" rid="bibr26-2048872612471215">26</xref></sup> However, one recent case report noted that, within 6 months of drug withdrawal, cardiomyocytes were reduced in size and devoid of intracellular vacuoles and myelin and curvilinear bodies were replaced by new contractile elements.<sup><xref ref-type="bibr" rid="bibr20-2048872612471215">20</xref></sup> Similar histological findings may be seen in skeletal muscle biopsies if neuromyotoxicity is present and may be diagnostic in cases where cardiac biopsy is contraindicated due to the severity of the patient’s condition.<sup><xref ref-type="bibr" rid="bibr24-2048872612471215">24</xref></sup></p>
<fig id="fig2-2048872612471215" position="float">
<label>Figure 2.</label>
<caption>
<p>Histological findings from right ventricular endomyocardial biopsy on light microscopy (top panels) and electron microscopy (bottom panels). (a) Myocyte hypertrophy and focal myocyte damage is demonstrated with vacuolization of the some of the cardiomyocytes. Some of these vacuoles contain central nuclei (arrows). (b) Masson’s trichrome stain highlights marked interstitial fibrosis (green/blue staining). (c and d) Electron microscopy showed cytoplasmic inclusion bodies: rounded aggregates of dark osmiophilic staining small bodies, some of which contain curvilinear and lamellar character (so-called ‘myelin bodies’) (arrows).</p>
</caption>
<graphic xlink:href="10.1177_2048872612471215-fig2.tif"/>
</fig>
<p>Risk factors for the development of HCQ-induced cardiotoxicity are thought to include older age, female sex, longer duration of therapy (&gt;10 years), elevated per-kilogram daily dose, pre-existing cardiac disease, and renal insufficiency.<sup><xref ref-type="bibr" rid="bibr8-2048872612471215">8</xref>,<xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref>,<xref ref-type="bibr" rid="bibr26-2048872612471215">26</xref>,<xref ref-type="bibr" rid="bibr32-2048872612471215">32</xref></sup> In the previously noted review,<sup><xref ref-type="bibr" rid="bibr7-2048872612471215">7</xref></sup> treatment duration prior to the diagnosis of cardiomyopathy ranged from 3 months to 27 years (mean 10 years). A more recent case describes a 30-year duration of therapy prior to the development of clinical heart failure.<sup><xref ref-type="bibr" rid="bibr13-2048872612471215">13</xref></sup> A wide range of cumulative dosage of antimalarial drugs in heart failure cases was also noted (270–9125 g). Guidelines for dosing of both CQ and HCQ are based on a large cohort study of 900 rheumatoid patients looking at risk for developing retinal toxicity.<sup><xref ref-type="bibr" rid="bibr33-2048872612471215">33</xref></sup> A safe daily dose where only reversible asymptomatic pigment changes were observed was defined as 6.0–6.5 mg/kg/day for HCQ. Our patient, 58 kg at the time of her last admission, would have been above this cut-off at 6.9 mg/kg/day. However, serious retinal toxicity level from this study was only reported from the level of 7.8 mg/kg/day.</p>
<p>Regarding presence of pre-existing cardiac disease, as noted above there were several factors in this case which may have contributed to myocardial and/or electrical dysfunction, including hypertension, venous thromboembolism, and chronic steroid use. It is also important to note that RA itself can be associated with a variety of cardiac manifestations,<sup><xref ref-type="bibr" rid="bibr34-2048872612471215">34</xref></sup> some of which, including myocarditis as previously noted, could present with similar features to those noted in our case. Rheumatoid vasculitis is typically seen in long standing ‘burnt-out’ RA, such as seems the case in this patient; one series of 50 patients documented cardiac manifestations including pericarditis and myocardial infarction in approximately one-third of patients.<sup><xref ref-type="bibr" rid="bibr35-2048872612471215">35</xref></sup> However, myocardial infarctions directly resulting from rheumatoid-associated coronary arteritis are rare, especially in patients without documented evidence of vasculitis in other major organs.<sup><xref ref-type="bibr" rid="bibr36-2048872612471215">36</xref><xref ref-type="bibr" rid="bibr37-2048872612471215"/>–<xref ref-type="bibr" rid="bibr38-2048872612471215">38</xref></sup> Meanwhile, RA is associated with a higher prevalence of symptomatic heart failure compared with individuals without RA which is not explained by traditional risk factors or clinical ischaemic disease, suggesting that chronic rheumatoid inflammation may account for the increased susceptibility.<sup><xref ref-type="bibr" rid="bibr39-2048872612471215">39</xref>,<xref ref-type="bibr" rid="bibr40-2048872612471215">40</xref></sup></p>
<p>Impairment in renal function has been proposed as a mechanism for toxicity given that these drugs undergo renal as well as hepatic excretion.<sup><xref ref-type="bibr" rid="bibr32-2048872612471215">32</xref></sup> Of note, many of the more recently described HCQ-induced cardiotoxicity cases occurred in patients with lupus nephritis.<sup><xref ref-type="bibr" rid="bibr11-2048872612471215">11</xref>,<xref ref-type="bibr" rid="bibr12-2048872612471215">12</xref>,<xref ref-type="bibr" rid="bibr14-2048872612471215">14</xref>,<xref ref-type="bibr" rid="bibr18-2048872612471215">18</xref></sup> Although she did not have SLE, the patient in this case had known chronic kidney disease.</p>
<p>In conclusion, we have presented, to our knowledge, only the fifth reported biopsy-proven case of HCQ cardiotoxicity, presenting as a rapidly evolving non-ischaemic biventricular dysfunction in a 52-year-old female with RA and multiple other comorbidities on long-term HCQ therapy. Although rare, the current case and the accompanying clinically orientated literature review highlights that antimalarial cardiotoxicity can be a fatal diagnosis with cardiac dysfunction persisting despite drug discontinuation. Given this, and the potential for reversibility, regular screening with 12-lead ECG and transthoracic echocardiography should be considered in HCQ- or CQ-treated patients in addition to ophthalmological screening, particularly if prolonged duration of treatment or other manifestations of toxicity.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors report no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2048872612471215">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morand</surname><given-names>EF</given-names></name>
<name><surname>McCloud</surname><given-names>PI</given-names></name>
<name><surname>Littlejohn</surname><given-names>GO</given-names></name>
</person-group>. <article-title>Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source> <year>1992</year>; <volume>51</volume>: <fpage>1318</fpage>–<lpage>1321</lpage>.</citation>
</ref>
<ref id="bibr2-2048872612471215">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Hydroxychloroquine therapy in rheumatic diseases</article-title>. <source>Ann Rheum Dis</source> <year>1995</year>; <volume>44</volume>: <fpage>6</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr3-2048872612471215">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Felson</surname><given-names>DT</given-names></name>
<name><surname>Anderson</surname><given-names>JJ</given-names></name>
<name><surname>Meenan</surname><given-names>RF</given-names></name>
</person-group>. <article-title>The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses</article-title>. <source>Ann Rheum Dis</source> <year>1990</year>; <volume>33</volume>: <fpage>1449</fpage>–<lpage>1461</lpage>.</citation>
</ref>
<ref id="bibr4-2048872612471215">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McAllister</surname><given-names>HA</given-names><suffix>Jr.</suffix></name>
<name><surname>Ferrans</surname><given-names>VJ</given-names></name>
<name><surname>Hall</surname><given-names>RJ</given-names></name>
<etal/></person-group>. <article-title>Chloroquine-induced cardiomyopathy</article-title>. <source>Arch Pathol Lab Med</source> <year>1987</year>; <volume>111</volume>: <fpage>953</fpage>–<lpage>956</lpage>.</citation>
</ref>
<ref id="bibr5-2048872612471215">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roos</surname><given-names>JM</given-names></name>
<name><surname>Aubry</surname><given-names>MC</given-names></name>
<name><surname>Edwards</surname><given-names>WD</given-names></name>
</person-group>. <article-title>Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with Fabry disease</article-title>. <source>Cardiovasc Pathol</source> <year>2002</year>; <volume>11</volume>: <fpage>277</fpage>–<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr6-2048872612471215">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Veinot</surname><given-names>JP</given-names></name>
<name><surname>Mai</surname><given-names>KT</given-names></name>
<name><surname>Zarychanski</surname><given-names>R</given-names></name>
</person-group>. <article-title>Chloroquine related cardiac toxicity</article-title>. <source>J Rheumatol</source> <year>1998</year>; <volume>25</volume>: <fpage>1221</fpage>–<lpage>1225</lpage>.</citation>
</ref>
<ref id="bibr7-2048872612471215">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costedoat-Chalumeau</surname><given-names>N</given-names></name>
<name><surname>Hulot</surname><given-names>JS</given-names></name>
<name><surname>Amoura</surname><given-names>Z</given-names></name>
<etal/></person-group>. <article-title>Cardiomyopathy related to antimalarial therapy with illustrative case report</article-title>. <source>Cardiology</source> <year>2007</year>; <volume>107</volume>: <fpage>73</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr8-2048872612471215">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baguet</surname><given-names>JP</given-names></name>
<name><surname>Tremel</surname><given-names>F</given-names></name>
<name><surname>Fabre</surname><given-names>M</given-names></name>
</person-group>. <article-title>Chloroquine cardiomyopathy with conduction disorders</article-title>. <source>Heart</source> <year>1999</year>; <volume>81</volume>: <fpage>221</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr9-2048872612471215">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reuss-Borst</surname><given-names>M</given-names></name>
<name><surname>Berner</surname><given-names>B</given-names></name>
<name><surname>Wulf</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Complete heart block as a rare complication of treatment with chloroquine</article-title>. <source>J Rheumatol</source> <year>1999</year>; <volume>26</volume>: <fpage>1394</fpage>–<lpage>1395</lpage>.</citation>
</ref>
<ref id="bibr10-2048872612471215">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freihage</surname><given-names>JH</given-names></name>
<name><surname>Patel</surname><given-names>NC</given-names></name>
<name><surname>Jacobs</surname><given-names>WR</given-names></name>
<etal/></person-group>. <article-title>Heart transplantation in a patient with chloroquine-induced cardiomyopathy</article-title>. <source>J Heart Lung Transplant</source> <year>2004</year>; <volume>23</volume>: <fpage>252</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr11-2048872612471215">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nord</surname><given-names>JE</given-names></name>
<name><surname>Shah</surname><given-names>PK</given-names></name>
<name><surname>Rinaldi</surname><given-names>RZ</given-names></name>
<etal/></person-group>. <article-title>Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature</article-title>. <source>Semin Ann Rheum Dis</source> <year>2004</year>; <volume>33</volume>: <fpage>336</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr12-2048872612471215">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keating</surname><given-names>RJ</given-names></name>
<name><surname>Bhatia</surname><given-names>S</given-names></name>
<name><surname>Amin</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction</article-title>. <source>J Am Soc Echocardiogr</source> <year>2005</year>; <volume>18</volume>: <fpage>981</fpage>.</citation>
</ref>
<ref id="bibr13-2048872612471215">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cotroneo</surname><given-names>J</given-names></name>
<name><surname>Sleik</surname><given-names>KM</given-names></name>
<name><surname>Rene Rodriguez</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Hydroxychloroquine-induced restrictive cardiomyopathy</article-title>. <source>Eur J Echocardiogr</source> <year>2007</year>; <volume>8</volume>: <fpage>247</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr14-2048872612471215">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soong</surname><given-names>TR</given-names></name>
<name><surname>Barouch</surname><given-names>LA</given-names></name>
<name><surname>Champion</surname><given-names>HC</given-names></name>
<etal/></person-group>. <article-title>New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy – a report of 2 cases</article-title>. <source>Hum Pathol</source> <year>2007</year>; <volume>38</volume>: <fpage>1858</fpage>–<lpage>1863</lpage>.</citation>
</ref>
<ref id="bibr15-2048872612471215">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manohar</surname><given-names>VA</given-names></name>
<name><surname>Moder</surname><given-names>KG</given-names></name>
<name><surname>Edwards</surname><given-names>WD</given-names></name>
<etal/></person-group>. <article-title>Restrictive cardiomyopathy secondary to hydroxychloroquine therapy</article-title>. <source>J Rheumatol</source> <year>2009</year>; <volume>36</volume>: <fpage>440</fpage>–<lpage>441</lpage>.</citation>
</ref>
<ref id="bibr16-2048872612471215">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JH</given-names></name>
<name><surname>Chung</surname><given-names>WB</given-names></name>
<name><surname>Kang</surname><given-names>JH</given-names></name>
<etal/></person-group>. <article-title>A case of chloroquine-induced cardiomyopathy that presented as sick sinus syndrome</article-title>. <source>Korean Circ J</source> <year>2010</year>; <volume>40</volume>: <fpage>604</fpage>–<lpage>608</lpage>.</citation>
</ref>
<ref id="bibr17-2048872612471215">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muthukrishnan</surname><given-names>P</given-names></name>
<name><surname>Roukoz</surname><given-names>H</given-names></name>
<name><surname>Grafton</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>Hydroxychloroquine-induced cardiomyopathy: a case report</article-title>. <source>Circ Heart Fail</source> <year>2011</year>; <volume>4</volume>: <fpage>e7</fpage>–<lpage>e8</lpage>.</citation>
</ref>
<ref id="bibr18-2048872612471215">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Newton-Cheh</surname><given-names>C</given-names></name>
<name><surname>Lin</surname><given-names>AE</given-names></name>
<name><surname>Baggish</surname><given-names>AL</given-names></name>
<etal/></person-group>. <article-title>Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure</article-title>. <source>N Engl J Med</source> <year>2011</year>; <volume>364</volume>: <fpage>1450</fpage>–<lpage>1460</lpage>.</citation>
</ref>
<ref id="bibr19-2048872612471215">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hartmann</surname><given-names>M</given-names></name>
<name><surname>Meek</surname><given-names>IL</given-names></name>
<name><surname>van Houwelingen</surname><given-names>GK</given-names></name>
<etal/></person-group>. <article-title>Acute left ventricular failure in a patient with hydroxychloroquine-induced cardiomyopathy</article-title>. <source>Neth Heart J</source> <year>2011</year>; <volume>19</volume>: <fpage>482</fpage>–<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr20-2048872612471215">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frustaci</surname><given-names>A</given-names></name>
<name><surname>Morgante</surname><given-names>E</given-names></name>
<name><surname>Antuzzi</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy</article-title>. <source>Int J Cardiol</source> <year>2012</year>; <volume>157</volume>: <fpage>117</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr21-2048872612471215">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>CY</given-names></name>
<name><surname>Wang</surname><given-names>FL</given-names></name>
<name><surname>Lin</surname><given-names>CC</given-names></name>
</person-group>. <article-title>Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia</article-title>. <source>Clin Toxicol (Phila)</source> <year>2006</year>; <volume>44</volume>: <fpage>173</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr22-2048872612471215">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rynes</surname><given-names>RI</given-names></name>
</person-group>. <article-title>Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment</article-title>. <source>Am J Med</source> <year>1983</year>; <volume>75</volume>: <fpage>35</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr23-2048872612471215">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maksymowych</surname><given-names>W</given-names></name>
<name><surname>Russell</surname><given-names>AS</given-names></name>
</person-group>. <article-title>Antimalarials in rheumatology: efficacy and safety</article-title>. <source>Semin Ann Rheum Dis</source> <year>1987</year>; <volume>16</volume>: <fpage>206</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr24-2048872612471215">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Estes</surname><given-names>ML</given-names></name>
<name><surname>Ewing-Wilson</surname><given-names>D</given-names></name>
<name><surname>Chou</surname><given-names>SM</given-names></name>
<etal/></person-group>. <article-title>Chloroquine neuromyotoxicity. Clinical and pathologic perspective</article-title>. <source>Am J Med</source> <year>1987</year>; <volume>82</volume>: <fpage>447</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr25-2048872612471215">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ratliff</surname><given-names>NB</given-names></name>
<name><surname>Estes</surname><given-names>ML</given-names></name>
<name><surname>Myles</surname><given-names>JL</given-names></name>
<etal/></person-group>. <article-title>Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy</article-title>. <source>N Engl J Med</source> <year>1987</year>; <volume>316</volume>: <fpage>191</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr26-2048872612471215">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>August</surname><given-names>C</given-names></name>
<name><surname>Holzhausen</surname><given-names>HJ</given-names></name>
<name><surname>Schmoldt</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Histological and ultrastructural findings in chloroquine-induced cardiomyopathy</article-title>. <source>J Mol Med (Berl)</source> <year>1995</year>; <volume>73</volume>: <fpage>73</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr27-2048872612471215">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mutru</surname><given-names>O</given-names></name>
<name><surname>Laakso</surname><given-names>M</given-names></name>
<name><surname>Isomaki</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Cardiovascular mortality in patients with rheumatoid arthritis</article-title>. <source>Cardiology</source> <year>1989</year>; <volume>76</volume>: <fpage>71</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr28-2048872612471215">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JS</given-names></name>
<name><surname>Judson</surname><given-names>MA</given-names></name>
<name><surname>Donnino</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Cardiac sarcoidosis</article-title>. <source>Am Heart J</source> <year>2009</year>; <volume>157</volume>: <fpage>9</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr29-2048872612471215">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>MR</given-names></name>
<name><surname>Cawley</surname><given-names>PJ</given-names></name>
<name><surname>Heitner</surname><given-names>JF</given-names></name>
<etal/></person-group>. <article-title>Detection of myocardial damage in patients with sarcoidosis</article-title>. <source>Circulation</source> <year>2009</year>; <volume>120</volume>: <fpage>1969</fpage>–<lpage>1977</lpage>.</citation>
</ref>
<ref id="bibr30-2048872612471215">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>KC</given-names></name>
<name><surname>Weiss</surname><given-names>RG</given-names></name>
<name><surname>Thiemann</surname><given-names>DR</given-names></name>
<etal/></person-group>. <article-title>Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy</article-title>. <source>J Am Coll Cardiol</source> <year>2008</year>; <volume>51</volume>: <fpage>2414</fpage>–<lpage>2421</lpage>.</citation>
</ref>
<ref id="bibr31-2048872612471215">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Piette</surname><given-names>JC</given-names></name>
<name><surname>Guillevin</surname><given-names>L</given-names></name>
<name><surname>Chapelon</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Chloroquine cardiotoxicity</article-title>. <source>N Engl J Med</source> <year>1987</year>; <volume>317</volume>: <fpage>710</fpage>–<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr32-2048872612471215">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mackenzie</surname><given-names>AH</given-names></name>
</person-group>. <article-title>Pharmacologic actions of 4-aminoquinoline compounds</article-title>. <source>Am J Med</source> <year>1983</year>; <volume>75</volume>: <fpage>5</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr33-2048872612471215">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mackenzie</surname><given-names>AH</given-names></name>
</person-group>. <article-title>Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials</article-title>. <source>Am J Med</source> <year>1983</year>; <volume>75</volume>: <fpage>40</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr34-2048872612471215">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Voskuyl</surname><given-names>AE</given-names></name>
</person-group>. <article-title>The heart and cardiovascular manifestations in rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source> <year>2006</year>; <volume>45</volume> <supplement>Suppl 4</supplement>: <fpage>iv 4</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr35-2048872612471215">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scott</surname><given-names>DG</given-names></name>
<name><surname>Bacon</surname><given-names>PA</given-names></name>
<name><surname>Tribe</surname><given-names>CR</given-names></name>
</person-group>. <article-title>Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases</article-title>. <source>Medicine (Baltimore)</source> <year>1981</year>; <volume>60</volume>: <fpage>288</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr36-2048872612471215">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sokoloff</surname><given-names>L</given-names></name>
</person-group>. <article-title>The heart in rheumatoid arthritis</article-title>. <source>Am Heart J</source> <year>1953</year>; <volume>45</volume>: <fpage>635</fpage>–<lpage>643</lpage>.</citation>
</ref>
<ref id="bibr37-2048872612471215">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cruickshank</surname><given-names>B</given-names></name>
</person-group>. <article-title>The arteritis of rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source> <year>1954</year>; <volume>13</volume>: <fpage>136</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr38-2048872612471215">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Albada-Kuipers</surname><given-names>GA</given-names></name>
<name><surname>Bruijn</surname><given-names>JA</given-names></name>
<name><surname>Westedt</surname><given-names>ML</given-names></name>
<etal/></person-group>. <article-title>Coronary arteritis complicating rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source> <year>1986</year>; <volume>45</volume>: <fpage>963</fpage>–<lpage>965</lpage>.</citation>
</ref>
<ref id="bibr39-2048872612471215">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicola</surname><given-names>PJ</given-names></name>
<name><surname>Maradit-Kremers</surname><given-names>H</given-names></name>
<name><surname>Roger</surname><given-names>VL</given-names></name>
<etal/></person-group>. <article-title>The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years</article-title>. <source>Ann Rheum Dis</source> <year>2005</year>; <volume>52</volume>: <fpage>412</fpage>–<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr40-2048872612471215">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crowson</surname><given-names>CS</given-names></name>
<name><surname>Nicola</surname><given-names>PJ</given-names></name>
<name><surname>Kremers</surname><given-names>HM</given-names></name>
<etal/></person-group>. <article-title>How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?</article-title> <source>Ann Rheum Dis</source> <year>2005</year>; <volume>52</volume>: <fpage>3039</fpage>–<lpage>3044</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>